The combination of CCND1 amplification and CDKN2A loss or CDK4/6 mutations has been associated with resistance mechanisms and shorter progression free survival in patients with BRAF-driven melanoma treated with BRAFi [42]. This evidence concerns the gene CDKN2A and melanoma.